Levetiracetam

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 559-573

  French, Jacqueline A ^a,b   Tonner, Françoise ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UCB PHARMA   (Belgium)

Author keywords

Activity in experimental models of seizures and epilepsy; Adjunctive therapy in refractory partial seizures in children; Effect of drugs on levetiracetam pharmacokinetics; Immediate release tablets; Levetiracetam; Mechanism of action of levetiracetam; Plasma concentration of levetiracetam in pregnancy

Indexed keywords

EID: 77953216281     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch44     Document Type: Chapter

References (105)

1. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2: 99-105.
2. Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992; 222: 193-203.
3. Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993; 232: 147-158.
4. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998; 353: 191-206.
5. Loscher W, Reissmuller E, Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res 2000; 40: 63-77.
6. Gower AJ, Hirsch E, Boehrer A, et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995; 22: 207-213.
7. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998; 284: 474-479.
8. Loscher W, Honack D. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia 2000; 41: 1499-1506.
9. Gower A, Baltes E, Nicolas J-M, Gobert J. Anticonvulsant effects of UCB-L059 in rats/absence of tolerance or discontinuation after chronic administration. Epilepsia 1993; 34(Suppl. 2): 50.
10. van Vliet EA, van Schaik R, Edelbroek PM, et al. Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 2008; 49: 1151-1159.
11. Potschka H, Baltes S, Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004; 58: 85-91.
12. Lamberty YMG, Klitgaard H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav 2000; 1: 333-342.
13. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101: 9861-9866.
14. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broadspectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720.
15. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286: 137-146.
16. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001; 42: 13-18.
17. Margineanu DG, Wulfert E. ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Eur J Pharmacol 1995; 286: 321-325.
18. Birnstiel S, Wulfert E, Beck SG. Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 611-618.
19. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000; 42: 281-285.
20. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707-724.
21. Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multipledose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 2006; 28: 734-744.
22. Fay MA, Sheth RD, Gidal BE. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther 2005; 27: 594-598.
23. Coupez R, Straetemans R, Sehgal G, Stockis A, Lu Z. Levetiracetam: Relative bioavailability and bioequivalence of a 10% oral solution (750mg) and 750-mg tablets. J Clin Pharmacol 2003; 43: 1370-1376.
24. Rouits E, Burton I, Guénolé E, Troenaru M, Stockis A, Sargentini-Maier ML. Pharmaco kinetics of levetiracetam XR 500 mg tablets. Epilepsy Res 2009; 84: 224-231.
25. Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res 2007; 76: 140-147. Erratum in: Epilepsy Res 2008; 78: 246.
26. Doheny HC, Ratnaraj N, Whittington MA, et al. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 1999; 34: 161-168.
27. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007; 48: 1111-1116.
28. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005; 46: 775-777.
29. Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 2003; 59: 621-630.
30. Fountain NB, Conry JA, Rodriguez-Leyva I, et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4-to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res 2007; 74: 60-69.
31. Lins RL, Otoul C, De Smedt F, Coupez R, Stockis A. Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int J Clin Pharmacol Ther 2007; 45: 47-54.
32. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225-230.
33. Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet 2007; 46: 503-512.
34. Zhao Q, Jiang J, Li X, et al. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol 2007; 63: 614-617.
35. Glauser TA, Mitchell WG, Weinstock A, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007; 48: 1117-1122.
36. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574-1579.
37. Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy. Clin Pharmacokinet 2008; 47: 333-341.
38. Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008; 17: 192-198.
39. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48: 1351-1359.
40. French J. Use of levetiracetam in special populations. Epilepsia 2001; 42: 40-43.
41. Keppra Product Information. Rev 26E, February 2008. Smyrna, Georgia, USA: UCB Inc.
42. Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005; 77: 529-541.
43. Strolin Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14: 301-319.
44. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005; 64: 1-11.
45. Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 2007; 48: 2111-2115.
46. De Deyn P, Bielen E, Saxens V, et al. Assessment of the safety of orally administered ucb L059 as add-on therapy in patients treated with antiepileptic drugs. Seizure 1992; 1: 7-15 (abstract).
47. Sharief M, Singh P, Sander JWAS, et al. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 1996; 9: 106-112.
48. Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40: 590-595.
49. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-87.
50. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
51. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179-1186.
52. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41: 1276-1283.
53. Lancelin F, Franchon E, Kraoul L, et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit 2007; 29: 576-583.
54. Guo T, Oswald LM, Mendu DR, Soldin SJ. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin Chim Acta 2007; 375: 115-118.
55. May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003; 25: 690-699.
56. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-1075.
57. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
58. Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 2006; 47: 1818-1821.
59. Snoeck E, Stockis A. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res 2007; 73: 284-291.
60. Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy (Cochrane Review). Cochrane Database Syst Rev 2001; (1): CD001901.
61. Leppik I, De Rue K, Edrich P, Perucca E. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. Epileptic Disord 2006; 8: 118-130.
62. French J, di Nicola S, Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 2005; 46: 1304-1307.
63. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurologica Scand 2006; 114: 157-168.
64. Peltola J, Coetzee C, Jiménez F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009; 50: 406-414.
65. Glauser TA, Ayala R, Elterman R, et al.; on behalf of the N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66: 1654-1660.
66. Pina-Garza JE, Nordli DR Jr, Rating D, et al.; and the LEV N01009 Pediatric Study Group. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 2009; in press (e-pub ahead of print; doi: 10.1111/j.1528-1167.2008.01981.x).
67. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
68. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607-616.
69. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. Placebocontrolled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 1751-1760.
70. Krauss G, Abou-Khalil B, Sheth S, et al. Efficacy of levetiracetam for treatment of drug-resistant generalized epilepsy. Epilepsia 2001; 42(Suppl. 7): 181.
71. Striano P, Sofia V, Capovilla G, Rubboli G, et al. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia 2008; 49: 425-430.
72. Rocamora R, Wagner K, Schulze-Bonhage A. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 2006; 15: 428-433.
73. Di Bonaventura C, Fattouch J, Mari F, et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 2005; 7: 231-235.
74. Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch Neurol 2004; 61: 1604-1607.
75. Altenmüller DM, Kühn A, Surges R, Schulze-Bonhage A. Termination of absence status epilepticus by low-dose intravenous levetiracetam. Epilepsia 2008; 49: 1289-1290.
76. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 2005; 14: 66-71.
77. Kinirons P, Ibrahim N, Murphy K, Delanty N. Dramatic response to levetiracetam in progressive myoclonic epilepsy. 2001; 42(Suppl. 7): 178.
78. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007; 69: 250-254.
79. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2: 209-212.
80. Cramer JA, Arrigo C, Van Hammee G. Effect of levetiracetam on epilepsy related quality of life. N132 Study Group. Epilepsia 2000; 41: 868-874.
81. Cramer JA. Quality of life and outcome measures for epilepsy clinical trials. Pharm World Sci 1997; 19: 227-230.
82. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann BP. Development and cross-cultural translation of a 31-item quality of life questionnaire (QOLIE-31). Epilepsia 1998; 39: 81-88.
83. Cramer JA, Van Hammée G; and the N132 Study Group. Maintenance of improvement in health related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 2003; 4: 118-123.
84. Otoul C, Arrigo C, van Rijckevorsel K, French JAZ. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005; 28: 72-78.
85. Harden C. Safety profile of levetiracetam. Epilepsia 2001; 42: 36-39.
86. Privitera MD, Edrich P, Godfroid P. Dose-response relationship of levetiracetam. Eur J Neurol 2002; 9(Suppl. 2): 177-178.
87. Ting T, French J, Cramer J. Infection rates among patients participating in clinical trials. Epilepsia 2000; 41(Suppl. 7): 253.
88. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4: 124-132.
89. Somerville ER. Aggravation of partial seizures by antiepileptic drugs. Is there evidence for clinical trials? Neurology 2002; 59: 79-83.
90. Goldstein J. Levetiracetam exacerbation of epilepsy. Epilepsia 2001; 42: 254-255.
91. Montouris G, Lippmann S, Williams R. Exacerbation of seizures: any relationship to dose escalation of levetiracetam (Keppra)? Epilepsia 2001; 42(Suppl. 7): 57.
92. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47: 77-90.
93. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu S, Stockis A. Levetiracetam intravenous infusion: a randomized, placebocontrolled safety and pharmacokinetic study. Epilepsia 2006; 47: 1128-1135.
94. Baulac M, Brodie MJ, Elger CE, et al. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 2007; 48: 589-592.
95. Shoaf TL, Lu Z, Yee KF, Gauer LJ. Evaluation of the relative risk of psychiatric and behavioral adverse events in pediatric patients with refractory partial seizures treated with levetiracetam-impact of prior history and a comparison with adult data. Epilepsia 2005; 46(Suppl. 8): 204-205.
96. Mintz M, Hunter S, Yang H, Schiemann J, Jones J, Stalvey T. Doubleblind, placebo-controlled, noninferiority study to evaluate the cognitive and neuropsychological effects of levetiracetam 20-60 mg/kg/day as adjunctive treatment versus placebo in pediatric patients with partialonset seizures. Epilepsia 2007; 48(Suppl. 6): 77417.
97. De La Loge C, Hunter S, Schiemann J, Yang H. Exploratory assessment of behavioral and emotional function in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized placebo-controlled trial. Neurology 2008; 70(Suppl. 1), A74, Abstract P02.094.
98. Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-1774.
99. Friedman D, French JA. Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology 2006; 66: 590-591.
100. Bronstein KS, Leppik I, Montouris G, et al. Keppra Pregnancy Registry. Epilepsia 2007; 48(Suppl. 6): 77107.
101. Rosetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol 2005; 54: 34-38.
102. Falip M, Carreño M, Amaro S, et al. Use of levetiracetam in hospitalized patients. Epilepsia 2006; 47: 2186-2188.
103. Salanova V, Manley M. Efficacy of levetiracetam in partial and generalized seizures: slower titration improves tolerability. Epilepsia 2001; 42(Suppl. 7): 185.
104. Ng Y, Wheless J. Levetiracetam: pediatric experience. Epilepsia 2001; 42(Suppl. 7): 55.
105. Wannag E, Eriksson A, Brockmeier K. Tolerability of levetiracetam in children with refractory epilepsy. Epilepsia 2001; 42(Suppl. 7): 57.